Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficaciuos in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society / Ghezzi, A.; L. M. E., Grimaldi; M. G., Marrosu; Pozzilli, Carlo; G., Comi; A., Bertolotto; M., Trojano; P., Gallo; R., Capra; D., Centonze; E., Millefiorini; S., Sotgiu; V., Brescia Morra; M. P., Amato; A., Lugaresi; G., Mancardi; D., Caputo; E., Montanari; L., Provinciali; L., Durelli; R., Bergamaschi; P., Bellantonio; M. R., Tola; S., Cottone; G., Savettieri; G., Tedeschi; Ms Sin Study, Group. - In: NEUROLOGICAL SCIENCES. - ISSN 1590-1874. - 32:2(2011), pp. 351-358. [10.1007/s10072-010-0469-0]
Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group-Italian Neurological Society
A. Ghezzi;POZZILLI, Carlo;
2011
Abstract
Three years after the introduction of natalizumab (NA) therapy for the second line treatment of relapsing-remitting multiple sclerosis (MS), Italian MS centers critically reviewed the scientific literature and their own clinical experience. Natalizumab was shown to be highly efficaciuos in the treatment of MS. However, the risk of progressive multifocal leukoencephalopathy was confirmed and defined better. This article summarizes the MS-SIN Study Group recommendations on the use of NA in MS, with particular reference to the appropriate selection and monitoring of patients as well as to the management of adverse events.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
